Frank G Sandmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/306703/publications.pdf

Version: 2024-02-01

22 papers

457 citations

933447 10 h-index 19 g-index

28 all docs 28 docs citations

28 times ranked

600 citing authors

#	Article	IF	CITATIONS
1	The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infectious Diseases, The, 2021, 21, 962-974.	9.1	117
2	Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. BMC Medicine, 2020, 18, 38.	5.5	52
3	Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison With Controls. Clinical Infectious Diseases. 2022. 75. e962-e973.	5.8	32
4	Estimating the opportunity costs of bedâ€days. Health Economics (United Kingdom), 2018, 27, 592-605.	1.7	31
5	Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients. Clinical Infectious Diseases, 2018, 67, 693-700.	5.8	28
6	Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics, 2013, 31, 781-797.	3.3	26
7	Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region: a mathematical modelling study. Lancet Regional Health - Europe, The, 2022, 12, 100267.	5.6	24
8	Burden, duration and costs of hospital bed closures due to acute gastroenteritis in England per winter, 2010/11–2015/16. Journal of Hospital Infection, 2017, 97, 79-85.	2.9	16
9	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. Health Technology Assessment, 2020, 24, 1-86.	2.8	16
10	Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis. Lancet Regional Health - Europe, The, 2022, 17, 100381.	5.6	15
11	Rapid COVID-19 vaccine rollout: immense success but challenges ahead. Lancet Infectious Diseases, The, 2022, 22, 302-304.	9.1	11
12	The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 475-486.	1.4	10
13	Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation. Value in Health, 2020, 23, 309-318.	0.3	7
14	Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy, 2013, 112, 285-296.	3.0	6
15	Optimizing Benefits of Testing Key Workers for Infection with SARS-CoV-2: A Mathematical Modeling Analysis. Clinical Infectious Diseases, 2020, 71, 3196-3203.	5.8	6
16	Factors that led to the implementation of the efficiency frontier approach in health economic evaluation in Germany: Do not avoid the elephant in the room. Comment on Klingler et al. (Health) Tj ETQq0 0 C) rg BT 0/0v	erlo s k 10 Tf 50
17	Augmenting contact matrices with time-use data for fine-grained intervention modelling of disease dynamics: A modelling analysis. Statistical Methods in Medical Research, 2022, 31, 1704-1715.	1.5	4
18	The impact of COVID-19 vaccination in prisons in England and Wales: a metapopulation model. BMC Public Health, 2022, 22, 1003.	2.9	4

#	Article	IF	CITATIONS
19	Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants. MDM Policy and Practice, 2018, 3, 238146831775192.	0.9	1
20	How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations. Value in Health, 2021, 24, 1391-1399.	0.3	1
21	O06.4â€Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HIPvac). , 2019, , .		0
22	Letters and debate. Society and Economy, 2014, 36, 427-433.	0.3	0